Close Menu

Meropenem Efflux in Pseudomonas aeruginosa at a Tertiary Care Hospital in Jamaica



Objective: Several mechanisms account for carbapenem resistance in Pseudomonas (P.) aeruginosa which is an emerging problem at a tertiary care hospital (TCH) in Jamaica.  The observed pattern of carbapenem resistance that results from efflux mechanisms is unique because it is specific to meropenem (MEM).  Investigation of efflux as a mechanism of carbapenem resistance needed to be done as the information obtained could inform therapeutic and infection control strategies.

Methodology: At the Microbiology Laboratory of a TCH in Jamaica, from May 2009 to March 2011, of 105 MDR Gram negative bacilli isolated from clinical specimen submitted for routine identification and susceptibility testing, all the MEM resistant Pseudomonas aeruginosa isolates (10) were selected.  They were tested for efflux using the efflux inhibitor PABN in a method described by Giske et al in 2008. 

Results: This study detected evidence of meropenem efflux in 80% of meropenem-resistant Pseudomonas aeruginosa implicated in nosocomial infections in a Jamaican hospital using the phenyl-arginine-β-naphthylamide inhibition assay.  Meropenem-efflux-positive isolates belonged to two unrelated chromosomal lineages.

Conclusion:  These results underscored the ned for improved surveillance and control to prevent this mechanism emerging in further P. aeruginosa strains

21 Jan, 2016
e-Published: 01 Mar, 2016

Pre-published Manuscript

This manuscript has been assigned to a volume and issue but has not yet been published. It is either being edited, typeset or is in the proof stage of publication.
In the pre-published stage, this manuscript may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in this manuscript will be made at the time of publication and will be reflected in the final electronic version of the issue. The editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.

Become a subscriber to access the full article.

Top of Page